Business Segments · Cost of Sales
Business Segments — Cost of Sales
Pfizer Business Segments — Cost of Sales increased by 31.1% to $3.03B in Q1 2026 compared to the prior quarter. This increase may warrant attention — for this metric, lower values are generally preferred.
Analysis
StatementSegment
CategoryProfitability
SignalLower is better
VolatilityStable
First reportedQ1 2025
Last reportedQ1 2026
Rolls up toTotal Cost of Revenue
How to read this metric
A decrease relative to revenue indicates improved manufacturing efficiency or favorable product mix shifts.
Detailed definition
The direct costs attributable to the production and distribution of the biopharma segment's products, including raw mate...
Peer comparison
Standard metric for assessing manufacturing efficiency and supply chain cost control in pharma.
Metric ID:
pfe_segment_biopharma_cost_of_salesHistorical Data
2 periods
| Q1 '25 | Q1 '26 | |
|---|---|---|
| Value | $2.31B | $3.03B |
| QoQ Change | — | +31.1% |
| YoY Change | — | +31.1% |
Range$2.31B – $3.03B
Avg YoY Growth+31.1%
Median YoY Growth+31.1%
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Pfizer's business segments — cost of sales?
- Pfizer (PFE) reported business segments — cost of sales of $3.03B in Q1 2026.
- What does business segments — cost of sales mean?
- The direct costs incurred to manufacture and deliver biopharma products.